Morgan Stanley Provention Bio, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $1.57 Million - $5.66 Million	233,944 Added 60.19%	622,650 $15 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $14,436 - $33,760	3,194 Added 0.83%	388,706 $4.11 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $170,145 - $278,780	49,605 Added 14.77%	385,512 $1.74 Million
Q2 2022 Oct 27, 2022	BUY	$3.65 - $7.3 $253,985 - $507,970	69,585 Added 26.13%	335,907 $1.34 Million
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $253,985 - $507,970	69,585 Added 26.13%	335,907 $1.34 Million
Q1 2022 Oct 27, 2022	SELL	$3.4 - $7.88 $236,589 - $548,329	-69,585 Reduced 20.72%	266,322 $1.95 Million
Q1 2022 May 13, 2022	BUY	$3.4 - $7.88 $303,154 - $702,604	89,163 Added 50.33%	266,322 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $200,446 - $264,990	-35,858 Reduced 16.83%	177,159 $996,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $1.21 Million - $1.77 Million	213,017 New	213,017 $1.36 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.